Phase 3 Autoimmune Clinical Trials
8 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche152 enrolled93 locationsNCT05503264
Recruiting
Phase 3
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Autoimmune Haemolytic Anaemia
Sanofi90 enrolled92 locationsNCT07086976
Recruiting
Phase 3
Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency
Autoimmune Prematur Ovarian Insuffience
Angelica Lindén Hirschberg40 enrolled2 locationsNCT07509840
Recruiting
Phase 3
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Autoimmune Pulmonary Alveolar Proteinosis
Savara Inc.5 enrolled1 locationNCT06431776
Recruiting
Phase 3
Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Primary Autoimmune Hemolytic Anemia
Assiut University30 enrolled2 locationsNCT05057468
Recruiting
Phase 3
LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.
Autoimmune Hypothyroidism
M. Medici600 enrolled19 locationsNCT05682482
Recruiting
Phase 3
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Demyelinating DiseasesMultiple SclerosisNervous System Diseases+3 more
Amsterdam UMC, location VUmc200 enrolled1 locationNCT05834855